Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease

Molecular Therapy - United States
doi 10.1038/mt.2011.290
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease

New England Journal of Medicine
Medicine
2015English

Clinical Benefit of Antisense Therapy in a Phase III Trial in Patients With CLL

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2007English

Antisense Oligonucleotide Therapy for Neurodegenerative Disease

Journal of Clinical Investigation
Medicine
2006English

Phase I/Ii Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination With Doxorubicin and Docetaxel in Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

A Phase 3 Clinical Trial With ISIS-TTRRx, a 2nd-Generation Antisense Oligonucleotide Targeting Transthyretin (TTR), for the Treatment of TTR Amyloid Cardiomyopathy

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2015English

GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Effect of Sulphasalazine in Patients With Active Crohn's Disease: A Controlled Double-Blind Study.

Gut
Gastroenterology
1981English

Platelet Count in Patients With Crohn's Disease

BMJ
1983English

Phase I Clinical Trial of Multiple-Peptide Vaccination for Patients With Advanced Biliary Tract Cancer

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy